for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Horizon Therapeutics PLC

HZNP.OQ

Latest Trade

87.93USD

Change

-1.95(-2.17%)

Volume

480,890

Today's Range

87.74

 - 

92.12

52 Week Range

41.23

 - 

97.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
89.88
Open
90.49
Volume
480,890
3M AVG Volume
36.92
Today's High
92.12
Today's Low
87.74
52 Week High
97.17
52 Week Low
41.23
Shares Out (MIL)
224.77
Market Cap (MIL)
20,139.81
Forward P/E
24.47
Dividend (Yield %)
--

Next Event

Horizon Therapeutics PLC at Bank of America Global Research Healthcare Conference (Virtual)

Latest Developments

More

Horizon Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.03

Horizon Therapeutics Q4 Sales Rose 105% To $745.3 Mln

Dassault Systemes: Horizon Therapeutics Expands Medidata Partnership

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Horizon Therapeutics PLC

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry

Biotechnology & Drugs

Contact Info

Connaught House

1St Floor, 1 Burlington Road

D04 C5Y6

Ireland

+353.1.7722100

https://www.horizontherapeutics.com/

Executive Leadership

Timothy P. Walbert

Chairman of the Board, President, Chief Executive Officer

Paul W. Hoelscher

Chief Financial Officer, Executive Vice President

Irina P. Konstantinovsky

Executive Vice President, Chief Human Resource Officer & Chief Diversity Officer

Barry J. Moze

Executive Vice President, Chief Administrative Officer

Brian K. Beeler

Executive Vice President, General Counsel

Key Stats

1.58 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.2K

2019

1.3K

2020

2.2K

2021(E)

2.8K
EPS (USD)

2018

1.830

2019

1.940

2020

3.880

2021(E)

3.673
Price To Earnings (TTM)
77.96
Price To Sales (TTM)
9.21
Price To Book (MRQ)
5.24
Price To Cash Flow (TTM)
35.67
Total Debt To Equity (MRQ)
66.89
LT Debt To Equity (MRQ)
66.48
Return on Investment (TTM)
5.19
Return on Equity (TTM)
4.61

Latest News

Latest News

Dr Reddy's loses bid to invalidate Horizon arthritis drug patents

Indian generic drugmaker Dr Reddy's Laboratories Ltd has lost a bid to invalidate patents on Horizon Therapeutics Plc and Nuvo Pharmaceuticals Inc's arthritis drug Vimovo.

Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy

Horizon Therapeutics Plc on Monday agreed to buy Viela Bio Inc for about $3.05 billion in a move to expand its rare-disease portfolio.

Horizon Therapeutics to buy Viela Bio for about $3.05 billion

Horizon Therapeutics said on Monday it will buy drug developer Viela Bio Inc for about $3.05 billion in an all-cash transaction. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

BRIEF-Horizon Therapeutics - CMS Issues Permanent J-Code For Tepezza Effective Oct 1

* HORIZON THERAPEUTICS PLC - CMS ISSUES PERMANENT J-CODE FOR TEPEZZA (TEPROTUMUMAB-TRBW) EFFECTIVE OCT. 1 Source text for Eikon: Further company coverage:

BRIEF-Hemoshear Therapeutics Achieves Milestone In Exclusive Drug Discovery Collaboration With Horizon Therapeutics In Gout

* HEMOSHEAR THERAPEUTICS ACHIEVES MILESTONE IN EXCLUSIVE DRUG DISCOVERY COLLABORATION WITH HORIZON THERAPEUTICS IN GOUT

BRIEF-Horizon Therapeutics says 79% Patients Achieved Complete Response Using Krystexxa With Methotrexate

* DATA PRESENTED ON KRYSTEXXA® (PEGLOTICASE INJECTION) CO-PRESCRIBED WITH AN IMMUNOMODULATOR ADDS TO GROWING BODY OF EVIDENCE FOR THIS TREATMENT APPROACH

BRIEF-Horizon Therapeutics Announces Redemption Of All $400 Mln of Exchangeable Senior Notes

* HORIZON THERAPEUTICS PLC - ISSUED A NOTICE OF REDEMPTION FOR ALL $400 MILLION OF 2.50% EXCHANGEABLE SENIOR NOTES DUE 2022 Source text for Eikon: Further company coverage:

BRIEF-Horizon Therapeutics Reports Qtrly Loss Per Share of $0.07

* INCREASING 2020 NET SALES GUIDANCE FOR TEPEZZA TO GREATER THAN $200 MILLION FROM $30 MILLION TO $40 MILLION

BRIEF-Horizon Therapeutics PLC Announces Availability Of PROCYSBI

* HORIZON THERAPEUTICS PLC ANNOUNCES AVAILABILITY OF PROCYSBI® (CYSTEAMINE BITARTRATE) DELAYED-RELEASE ORAL GRANULES IN PACKETS IN THE UNITED STATES

BRIEF-Horizon Therapeutics Announces CEO's FY 2019 Total Compensation

* HORIZON THERAPEUTICS PLC SAYS CEO TIMOTHY WALBERT'S FY 2019 TOTAL COMPENSATION WAS $13.9 MILLION VERSUS $16.8 MILLION IN FY 2018 - SEC FILING

BRIEF-India's Lupin Launches Generic Version Of Horizon Therapeutics' Arthritis Drug Vimovo

* LAUNCHES AUTHORIZED GENERIC FOR HORIZON THERAPEUTICS' VIMOVO DELAYED RELEASE TABLETS IN U.S. Source text for Eikon: Further company coverage:

Horizon's prices thyroid eye disease therapy at $14,900 per vial

Horizon Therapeutics Plc on Tuesday priced its treatment for thyroid eye disease at $14,900 per vial following the U.S. FDA approval and said the drug would be available in the United States in the coming weeks.

FDA approves Horizon's drug for thyroid eye disease

The U.S. Food and Drug Administration has approved Horizon Therapeutics Plc's treatment for thyroid eye disease, the agency said on Tuesday.

FDA panel votes unanimously in favor of Horizon's thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of Horizon Therapeutics Plc's experimental treatment for active thyroid eye disease, taking the drug closer towards potential approval.

FDA panel votes in favour of Horizon's active thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday unanimously voted in favor of Horizon Therapeutics Plc's experimental treatment for thyroid eye disease (TED), taking the drug a step towards potential approval.

IN BRIEF: Fed Circuit shuts down Actavis generic for Horizon’s osteoarthritis drug

Actavis Laboratories UT cannot offer a generic version of Horizon Pharma’s Pennsaid 2% serum until one of the patents on it expires, the U.S. Court of Appeals for the Federal Circuit held Thursday.

Recordati to seek Canadian approval for kidney disease drug

Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03

* REPORTS STRONG FIRST-QUARTER 2018 ORPHAN AND RHEUMATOLOGY NET SALES GROWTH; INCREASES FULL-YEAR 2018 GUIDANCE AND ANNOUNCES NEW COMPANY OPERATING STRUCTURE TO ENHANCE FOCUS ON RARE DISEASES

BRIEF-AGC Biologics Enters Commercial Manufacturing Agreement With Horizon Pharma

* AGC BIOLOGICS SAYS ENTERS INTO COMMERCIAL MANUFACTURING AGREEMENT WITH HORIZON PHARMA PLC FOR COMMERCIAL SUPPLY OF TEPROTUMUMAB Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up